Katherine Austman, MD
Addiction Medicine · Gibson City, ILNPI 1396739462
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Orexo US, Inc. at 24.4% of the total. That places this record below the midpoint for addiction medicine clinicians in IL, where the typical reported total is $234.
Across 12 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Orexo US, Inc.$55
- Axsome Therapeutics, Inc.$42
- Biofire Diagnostics, LLC$36
- Novo Nordisk$18
- Indivior Inc.$18
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$16
- plus $41 from 3 others
What the payments were for
- Food & beverage$226100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Orexo US, Inc. | 3 | $55 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Biofire Diagnostics, LLC | 1 | $36 |
| Novo Nordisk | 1 | $18 |
| Indivior Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| AbbVie | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $13 |
| GSK | 1 | $13 |
How this compares
$226 in reported general payments places this provider in the 45th percentile of 47 addiction medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 21 | $16,596 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 66 | $8,853 |
| PremproEstrogen,con/M-Progest Acet | 12 | $2,881 |
| Novolog FlexpenInsulin Aspart | 11 | $1,330 |
| Acyclovir | 15 | $376 |
| Simvastatin | 59 | $370 |
| Amlodipine Besylate | 40 | $298 |
| Levothyroxine Sodium | 46 | $242 |
| Metformin Hcl | 23 | $209 |
| Losartan Potassium | 23 | $178 |
| Sertraline Hcl | 14 | $170 |
| Atorvastatin Calcium | 27 | $160 |
| Metoprolol Succinate | 15 | $145 |
| Amitriptyline Hcl | 15 | $144 |
| Alendronate Sodium | 17 | $121 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Gibson City
- Roueen RafeyanChicago$2.4M
- Abhinav SinglaJoliet$115K
- Leonard SpishakoffRomeoville$11K
- Phillip HeldingHinsdale$8K
- Adeyemi FatokiOttawa$8K
- Michael BlainEldorado$6K
- Albert TanlimWatseka$5K
- Francesco TaniChicago$4K
- Neha DattaOrland Park$4K
- Paul BonucciPrinceton$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.